Print PDF
Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars

On May 4, Axinn partners Ted Mathias and Stacie Ropka participated in a video interview with The Center for Biosimilars. They discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).

Click to access part 1, part 2, and part 3 of the interview.  

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.